Compass Therapeutics Inc. (CMPX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Compass Therapeutics Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 7 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 1.90 $ — 4% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 347.4% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 9
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.43 | -0.59 – -0.33 | -2 | -3.4% | 12 |
| 12/31/2027 | -0.46 | -0.82 – -0.13 | 25 | -6.5% | 12 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.10 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.11 | – | 0 | -100.00 | – | -9 | -9 |
| 2025: Q1 | -0.12 | – | 0 | – | – | -13 | -13 |
| 2025: Q2 | -0.14 | – | 0 | -100.00 | – | -12 | -12 |
| 2025: Q3 | -0.10 | – | 0 | – | – | -11 | -11 |
| 2025: Q4 | -0.09 | – | 0 | – | – | -13 | -13 |
| 2026: Q1 | -0.10 | – | 0 | – | – | -17 | -17 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2018 | 0 | -38 | -38 | -7.66 | -34 | -85 | 65 |
| 2019 | 0 | -34 | -35 | -0.67 | -32 | -119 | 30 |
| 2020 | 0 | -28 | -30 | -0.52 | -27 | 40 | 52 |
| 2021 | 0 | -82 | -82 | -1.31 | -20 | 140 | 154 |
| 2022 | 0 | -42 | -39 | -0.37 | -34 | 182 | 200 |
| 2023 | 0 | -50 | -42 | -0.33 | -41 | 149 | 157 |
| 2024 | 1 | -57 | -49 | -0.36 | -45 | 125 | 140 |
| 2025 | 0 | -73 | -66 | -0.42 | -49 | 197 | 220 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Compass Therapeutics, Inc. , a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States.
| Employees | 39 |
|---|---|
| Headquarters | Boston, MA |
| Address | 80 Guest Street, 02135 Boston, United States |
| Phone | 617 500 8099 |
| Website | compasstherapeutics.com |
| IPO Date | 5. Apr 2021 |
| ISIN | US20454B1044 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Thomas J. Schuetz M.D., Ph.D. | CEO & Vice Chairman | 1961 |
| Barry Shin J.D., M.B.A. | Chief Financial Officer | 1972 |
| Jonathan E. Anderman J.D. | Senior VP, General Counsel & Corporate Secretary | 1983 |
| Neil L. Lerner CPA | Senior VP & Chief Accounting Officer | 1967 |
| Bing Gong Ph.D. | Chief Scientific Officer | 1976 |
| Anna Gifford | Senior Manager of Communications & Chief of Staff | – |
| Karin Herrera B.A. | Senior VP & Head of Clinical Operations | – |
| James Kranz Ph.D. | VP and Head of Chemistry Manufacturing & Controls | – |
| Cynthia A. Sirard M.D., Ph.D. | Chief Medical Officer | 1970 |
| Arjun Prasad M.B.A., M.P.H. | Chief Commercial Officer | 1978 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.